EUVIMEDEUVIMED entdecken
ÄquivalenzstudieRandomisierte kontrollierte StudieOpen Access

Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial

Nirupa Chandorkar iD, Gunjana Kumar, Gurnoor Singh, Kaifi Siddiqui, Jai Krishan Mittal, Surendra Singh, Anil Galwa, Amit Kumar

Pediatric Pulmonology · 2026-05 · 61 (5)

DOI: 10.1002/ppul.71677 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift Pediatric Pulmonology, online erschienen am 26.05.2026. Verfasst von Nirupa Chandorkar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, National Institute of Medical Science and Research Hospital, Nims University Rajasthan, Jaipur, India. Hauptthemen laut MEDLINE: Apnea, Caffeine, Central Nervous System Stimulants, Infant, Premature, Diseases. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

While caffeine therapy is well‐established for managing apnea of prematurity (AOP), standardized protocols for its discontinuation are lacking. This study evaluated whether earlier cessation at 33 weeks postmenstrual age (PMA) is as safe as conventional discontinuation at 34 weeks.

Methods

Preterm neonates (26–32 weeks of gestation) on caffeine for AOP, who were off respiratory support and apnea‐free for 5 consecutive days by 33 weeks PMA, were randomized to early discontinuation (Group A) or conventional discontinuation at 34 weeks PMA (Group B). The primary outcome was recurrence of apnea (RAP) post‐cessation.

Results

Apnea recurrence was similar between groups (13.7% vs. 10%; OR 1.44, p = 0.71). Caffeine duration was significantly shorter in Group A (21.5 vs. 28.5 days, p = 0.024). No significant differences were noted in secondary outcomes or neonatal morbidities.

Conclusions

Early discontinuation of caffeine at 33 weeks PMA in stable preterm neonates appears safe and may reduce drug exposure without increasing apnea risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApneaCaffeineCentral Nervous System StimulantsInfant, Premature, DiseasesFemaleHumansInfant, NewbornMaleGestational AgeInfant, PrematureRecurrenceTreatment InterruptionTreatment Outcome

Stichwörter der Autor:innen

apnea of prematuritycaffeinediscontinuationpreterm neonaterandomized trial

Substanzen

CaffeineCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Department of Neonatology, National Institute of Medical Science and Research Hospital, Nims University Rajasthan, Jaipur, India.
  • Department of Pediatrics, National Institute of Medical Science and Research Hospital, Nims University Rajasthan, Jaipur, India.

ORCID-Profile: Nirupa Chandorkar

Zitieren

APA

Chandorkar, N., Kumar, G., Singh, G., Siddiqui, K., Mittal, J. K., Singh, S., Galwa, A., & Kumar, A. (2026). Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial. Pediatric Pulmonology, 61(5). https://doi.org/10.1002/ppul.71677

Vancouver

Chandorkar N, Kumar G, Singh G, Siddiqui K, Mittal JK, Singh S, et al. Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial. Pediatric Pulmonology. 2026;61(5). doi:10.1002/ppul.71677

BibTeX
@article{Chandorkar2026,
  author = {Chandorkar, Nirupa and Kumar, Gunjana and Singh, Gurnoor and Siddiqui, Kaifi and Mittal, Jai Krishan and Singh, Surendra and Galwa, Anil and Kumar, Amit},
  title = {Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {5},
  doi = {10.1002/ppul.71677}
}
Kostenlos starten →